Tenax Therapeutics (NASDAQ:TENX) Stock Rating Upgraded by Lifesci Capital

Tenax Therapeutics (NASDAQ:TENX) was upgraded by equities researchers at Lifesci Capital to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Monday, December 22nd. Guggenheim reaffirmed a “buy” rating and issued a $25.00 price target (up from $14.00) on shares of Tenax Therapeutics in a report on Wednesday, December 17th. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $22.50.

Tenax Therapeutics Stock Down 2.9%

Shares of NASDAQ:TENX opened at $14.19 on Thursday. The firm has a market capitalization of $88.55 million, a PE ratio of -10.67 and a beta of 1.41. The company has a 50-day moving average price of $13.30 and a two-hundred day moving average price of $9.90. Tenax Therapeutics has a twelve month low of $4.63 and a twelve month high of $18.38.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.88. Analysts anticipate that Tenax Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Tenax Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC purchased a new stake in shares of Tenax Therapeutics in the 4th quarter valued at about $5,353,000. Siren L.L.C. grew its holdings in shares of Tenax Therapeutics by 21.2% during the fourth quarter. Siren L.L.C. now owns 427,141 shares of the specialty pharmaceutical company’s stock worth $5,207,000 after purchasing an additional 74,700 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Tenax Therapeutics in the third quarter worth approximately $2,680,000. Millennium Management LLC increased its position in shares of Tenax Therapeutics by 34.2% in the third quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock worth $2,387,000 after purchasing an additional 79,998 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in Tenax Therapeutics by 68.2% in the fourth quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company’s stock valued at $3,634,000 after purchasing an additional 120,944 shares in the last quarter. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.